Independent news has never been so important.

Get Democracy Now! delivered to your inbox every day! Don't worry, we won't share or sell your information.

Preliminary Findings Show No Benefits of Remdesivir, Hydroxychloroquine for COVID-19

HeadlineApr 24, 2020

In medical news, a draft manuscript of a report from a long-awaited clinical trial in China finds the antiviral drug remdesivir failed to lower the death rates or recovery times of COVID-19 patients. The findings have not yet passed peer review.

Preliminary results of a study by the New York state Department of Health showed the drug touted by President Trump as a curative for COVID-19 — hydroxychloroquine — had no effect on patients’ recoveries.

The original content of this program is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License. Please attribute legal copies of this work to democracynow.org. Some of the work(s) that this program incorporates, however, may be separately licensed. For further information or additional permissions, contact us.

Non-commercial news needs your support

We rely on contributions from our viewers and listeners to do our work.
Please do your part today.
Make a donation
Top